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Abstract
Purpose In 1997, Vogelzang et al. reported that 61 % of pa-
tients with cancer indicated fatigue impacted daily life more
than pain, and only 37% of oncologists shared this perception.
We provide an update to this study, which can help prioritize
symptom assessment and management in the clinic. Study
aims were to determine and compare perceptions of patients
with cancer and health care providers (HCPs) of the impact of
fatigue and pain.
Methods A random sample of patients with cancer was re-
cruited in the USA by Harris Poll Online and Schlesinger
Associates. Oncology HCPs were recruited by Food and
Drug Research, Inc. and Toluna, Inc.
Results From June to November 2012, 550 of 1122 eligible
patients (49 %), 400 of 533 eligible oncologists (75 %), and
400 of 617 eligible oncology nurses (65 %) completed a sur-
vey. Of patients, 58 % reported that fatigue affected their daily
lives more than pain while undergoing treatment with chemo-
therapy versus 29 % of oncologists and 25 % of oncology
nurses that had this perception. Ninety-eight percent of pa-
tients reported experiencing fatigue, whereas 72 % of oncol-
ogists and 84 % of oncology nurses thought this was the case.
Eighty-six percent of patients reported pain while undergoing
treatment with chemotherapy, whereas 36 % of oncologists
and 51 % of oncology nurses believed this occurred. Nausea
and vomiting felt by HCPs were the most concerning symp-
toms for patients (88 %).
Conclusions This study shows the importance of assessing
symptoms by direct patient report during chemotherapy treat-
ment. HCPs continue to underestimate the prevalence and
importance of fatigue and pain for patients with cancer, a
finding that may alter the management of treatment-related
symptoms and may influence the development of patient
symptom management plans.
Keywords Fatigue . Pain . Neoplasms . Drug therapy
Introduction
Fatigue is a common problem among people with cancer. It is
associated with the disease itself and many of its treatments.
The estimated prevalence of fatigue among patients with can-
cer receiving chemotherapy ranges from 17 to 82 % [1–3].
Fatigue has a significant adverse impact on daily activities
and is one of the primary drivers of poor quality of life
(QOL) [4–6]. Information about patient and health care pro-
vider (HCP) perceptions regarding the importance of fatigue
in cancer is lacking.
In 1997, Vogelzang et al. reported that 61 % of patients
with cancer indicated fatigue impacted daily life more than
pain, whereas only 37 % of oncologists shared this perception
[7]. Other more recent studies have continued to demonstrate
a poor correlation between clinician and patient-reported
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subjective symptoms such as fatigue and pain [8, 9]. Pain
management has also been shown to be inadequate in up to
1/3 of patients with solid tumors [10].
The importance of assessing patient-reported outcomes
(PROs) in routine clinical practice and the integration of
PROs with electronic health records to improve outcomes
has recently been shown in a number of studies [11–13].
Efforts to standardize collection of PROs in electronic health
records and recommendations for the multidisciplinary clini-
cal management team to act on information gathered from
PRO assessments have also been proposed [14, 15].
Underscoring the importance of PROs in the regulatory land-
scape, the US FDA has provided guidance for the collection of
PRO endpoints in clinical trials, and the European Medicines
Agency recently highlighted the value of PROs in developing
therapies for patients with cancer [16, 17].
With recent changes in the management of cancer, longer
life expectancy, and a heightened awareness of supportive
care issues, an updated analysis to evaluate the current preva-
lence and perception of fatigue in current oncology practice
was needed. We aimed to determine whether HCP awareness
of the substantial impact of fatigue on the lives of patients with
cancer has led to a decrease in its prevalence.We also aimed to
compare perspectives on fatigue to similar perspectives on
pain in cancer. Given what has been reported by various au-
thors over the last two decades, we aimed to determine wheth-
er HCP perceptions of the impact of fatigue relative to pain on
patients with cancer and treated with chemotherapy are more
closely aligned with patient reports than has been historically
observed [7–10].
Objectives
The primary objective of this study was to estimate the pro-
portion of patients with cancer who report that fatigue affected
their daily life more than pain while undergoing chemotherapy
and to compare this proportion to that of providers (oncolo-
gists and oncology nurses) who were asked a similar question.
Secondary objectives were to estimate the prevalence of
fatigue and pain among patients treated with chemotherapy,
to determine provider estimated proportions of fatigue and
pain among their patients receiving chemotherapy, and to
compare the patient-reported prevalence and provider-
reported estimated proportions of fatigue and pain.
Methods
A sample of patients from the general US population was
recruited via email by online survey firms Harris Poll
Online and Schlesinger Associates. Oncology HCPs prac-
ticing in the USA were recruited via email by Food and
Drug Research, Inc. and Toluna, Inc. Data consisted of
patient-reported demographic, disease, treatment charac-
teristics, and survey responses from patients with cancer
and oncology HCPs. Quorum Review Institutional Review
Board granted an exception to the formal informed consent
process because the survey did not capture any patient identi-
fying information.
Statistical analyses
This was an estimation study; no formal hypothesis testing
was planned. Proportions of patients and HCP perceptions
were estimated for fatigue affecting daily life more than pain,
pain affecting daily life more than fatigue, experiencing fa-
tigue, and experiencing pain. Differences between patients
and HCPs perceptions were computed.
Patient eligibility criteria
To be eligible to participate, patients had to be age 18 or older,
have a diagnosis of a non-hematologic tumor, have received at
least 2 months of chemotherapy and/or targeted/biologic ther-
apy initiated less than 14 months before the date of survey
initiation, and received chemotherapy within 1 year of partic-
ipation in the survey. Exclusion criteria included a history of
myelodysplastic syndrome or hematologic malignancy such
as leukemia, lymphoma, Hodgkin’s disease, or multiple mye-
loma; having received a bonemarrow or stem cell transplant at
any time; and having participated in a previous survey of any
kind within the last 3 months. Patients were also excluded if
they resided outside the USA or if they received the last dose
of chemotherapy more than 1 year from the date of survey
completion.
HCP eligibility criteria
To be eligible, oncologists and oncology nurses had to
have spent at least 75 % of their work time in patient care
and at least 50 % of their work time providing direct care
for adult patients with solid tumors receiving chemother-
apy. Oncologists were required to be currently employed
≥30 h/week as a medical oncologist, hematologist/oncol-
ogist, or gynecologic oncologist and in practice for 2 years
or more after completing fellowship. Oncology nurses
were required to be currently employed ≥30 h/week as a
registered nurse or nurse practitioner and to have cared for
at least 100 patients with solid tumors receiving chemo-
therapy in the past 2 years. Exclusion criteria included
primary practice in hematology, radiation oncology, or
surgical oncology.
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Results
Patient baseline demographics and disease characteristics
From June to November 2012, 550 of 1122 eligible pa-
tients (49 %) completed a survey (Appendix). Of these,
144 (26 %) were men, 406 (74 %) were women; median
(minimum, maximum) age for all patients was 58 (19,
91) years; 171 (31 %) patients were ≥65 years of age; and
self - ra ted Eastern Cooperat ive Oncology Group
Performance Status was 0 or 1 for 41 % of patients, 2 for
31 % of patients, and ≥3 for 27 % of patients. Patient-
reported most recently diagnosed cancer (number [%]) in-
cluded breast (212 [39]), lung (74 [14]), colon (47 [9]),
ovarian (44 [8]), prostate (30 [6]), uterine (16 [3]), liver
(15 [3]), brain (13 [2]), bladder (12 [2]), and rectal (12
[2]). Metastatic and/or stage 4 disease was reported by
235 (43 %) patients. Five hundred twenty-four patients
(95 %) had received or were currently receiving chemo-
therapy, while 147 (27 %) patients had received or were
currently receiving targeted or biologic therapy. More than
half of patients (298 [54 %]) had received or were currently
receiving radiation, and 121 (22 %) had received or were
currently receiving hormonal therapy. Most patients (458
[83 %]) had received the last dose of chemotherapy or
targeted/biologic therapy within the previous 6 months,
and more than half of patients (293 [53 %]) were receiving
some type of therapy at the time of the survey (Table 1).
HCP baseline demographics
From June to November 2012, 400 of 533 eligible oncologists
(75 %) and 400 of 617 eligible oncology nurses (65 %) com-
pleted a survey (Appendix). The median number of years in
oncology practice was 15 years, with a minimum of 2 and a
maximum of 45 years. Most were single specialty group prac-
tices (40.5 %), followed by academic or teaching hospitals
(19.4 %), and multiple specialty private group practices
(17.3 %). Community-based hospital and solo practices
accounted for 15.4 and 7.5 % of practices, respectively.
Patients with lung, breast, colorectal, prostate, ovarian, lym-
phoma, leukemia, as well as other cancers were treated at
these practices (Table 2).
Primary endpoint
The majority (58 %) of patients reported that fatigue had
a greater impact than pain on their daily lives while
undergoing treatment with chemotherapy, whereas 29 %
of oncologists and 25 % of nurses had this perception
(Fig. 1).








Black or African American 45 (8.2)
American Indian or Alaska Native 4 (0.7)
Asian 7 (1.3)
Some other race 16 (2.9)
Prefer not to answer 1 (0.2)
Hispanic, Latino, or Spanish origin—n (%)
No, not of Hispanic, Latino, or Spanish origin 525 (95.5)
Mexican, Mexican American, Chicano 6 (1.1)
Cuban 2 (0.4)
Another Hispanic, Latino, or Spanish origin 15 (2.7)
Prefer not to answer 2 (0.4)
Age (years)
Median 58.0
Q1, Q3 49.0, 66.0













Duration from cancer diagnosis (years)
Median 1.7
Q1, Q3 0.8, 4.7
Min, max 0, 51
Cancer treatment—n (%)
Chemotherapy 524 (95.3)
Radiation therapy 298 (54.2)
Hormonal therapy 121 (22.0)
Targeted therapy or biologic therapy 147 (26.7)
Completed most recent chemotherapy or targeted/biologic
therapy—n (%)
Currently being treated 293 (53.3)
0–3 months ago 99 (18.0)
4–6 months ago 66 (12.0)
7–9 months ago 33 (6.0)
10–12 months ago 59 (10.7)
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Secondary endpoints
About one fifth (18 %) of patients reported that pain had a
greater impact than fatigue on their daily lives while undergo-
ing treatment with chemotherapy, whereas 30 % of oncolo-
gists and 29 % of nurses had this perception. The perception
that fatigue and pain had an equal impact on daily life was
reported by 24% of patients, 42% of oncologists, and 46% of
nurses (Fig. 1).
Nearly all patients (536 of 550; 97.5 %) reported that they
experienced some degree of fatigue while undergoing treat-
ment with chemotherapy. HCPs asked to estimate the propor-
tion of patients that experienced fatigue during chemotherapy
reported that 77.9 % of patients experienced fatigue overall,
an underestimate of 20 % (95 % CI, 18 %, 21 %). Most
patients (474 of 550; 86.2 %) also experienced pain while
undergoing treatment with chemotherapy. HCPs asked to es-
timate the proportion of patients that experienced pain during
chemotherapy reported that 43.6 % of patients experienced
pain overall, an underestimate of 43% (95%CI, 39%, 46%).
On scales of 0 to 10, where 0 represented no fatigue and 10
represented the most severe fatigue, the mean (standard devi-
ation [SD]) fatigue severity score reported by patients was 7.0
(2.6) and the mean (SD) pain severity score was 5.2 (3.3). The
survey results demonstrated that nausea and vomiting were
the side effects that 88 % of HCPs felt most concerned pa-
tients, and nausea/vomiting were the side effects from chemo-
therapy that most health care providers (97 %) reported typi-
cally documenting in the patient chart during chemotherapy
treatment.
Ad hoc subset analyses were performed on categories
by tumor type, ECOG performance status score, gender,
metastatic disease status, and time since diagnosis
(Table 3). For all tumor types combined, more patients
reported fatigue than pain during cancer treatment (98 vs
86 %). Fatigue ranged from 91.3 % in other tumor types to
100 % for gynecologic and lung tumors; the range for pain
was 74.5 % for gastrointestinal tumors to 97.1 % for gyne-
cologic tumors. In patients with ECOG performance status
scores of 0 and 1, 15 of 30 (50 %) and 37 of 198 (18.7 %)
patients reported no pain, whereas fatigue was reported by
70 and 98 %, respectively. Nearly all patients with ECOG
performance status of 1 to 4 reported experiencing fatigue.
Time since diagnosis did not appear to impact reporting of
pain or fatigue.
Discussion
This study emphasizes the importance of assessing symp-
toms by direct patient report while undergoing treatment
with chemotherapy. There continues to be a gap between
HCPs and patients in the relative emphasis placed on fa-
tigue versus pain. In 1997, Vogelzang et al. reported a 24 %
difference between patients (61 %) and oncologists (37 %)
of the perception that fatigue impacted daily life more than
pain [7]. Our study showed a 29 % difference between
patients (58 %) and oncologists (29 %) and a 33 % differ-




ECOG performance status—n (%)
0: normal activity, without symptoms 30 (5.5)
1: some symptoms but do not require bed rest
during waking day
198 (36.0)
2: require bed rest for less than 50 % of waking
day
173 (31.5)
3: require bed rest for more than 50 % of
waking day
135 (24.5)
4: unable to get out of bed 14 (2.5)
Table 2 HCP practice demographics
Overall (N= 800)
Number of years in oncology practice
Median 15.0
Q1, Q3 10.0, 23.0
Min, max 2, 45
Type of practice—n (%)
Academic 155 (19.4)
Community 123 (15.4)
Multiple specialty private group 138 (17.3)





Q1, Q3 15.0, 25.0
Breast cancer
Median 25.0
Q1, Q3 20.0, 30.0
Colorectal cancer
Median 19.0
Q1, Q3 15.0, 20.0
Prostate cancer
Median 10.0
Q1, Q3 5.0, 15.0
Ovarian cancer
Median 5.0
Q1, Q3 2.0, 10.0
Lymphoma
Median 10.0
Q1, Q3 5.0, 15.0
Leukemia
Median 5.0
Q1, Q3 2.0, 10.0
Other
Median 0.0
Q1, Q3 0.0, 3.0
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perception that fatigue impacted daily life more than pain.
Clearly, there remains a discrepancy between patients and
HCPs regarding the relative importance of fatigue versus
pain while undergoing treatment with chemotherapy; pain
is a symptom that may be more readily monitored, tracked,
and treated than fatigue for HCPs in the clinic. Efforts to
educate patients of the importance of fatigue as a symptom
of chemotherapy that should be recognized and treated
should continue, and educational programs for multidisci-
plinary oncology teams should include components that
focus on fatigue symptom information gathering. Factors
that contribute to fatigue, such as anemia due to
myelosuppression, anemia due to dehydration, or sleep dis-
turbances, should also be considered by HCPs.
Fatigue can be both a manifestation of cancer treatment, as
well as a symptom attributable to the cancer itself, which may
lead to misattribution of fatigue symptoms and the impact of
these symptoms on patient functioning. Furthermore, esti-
mates of fatigue among patients with cancer receiving chemo-
therapy vary widely in the literature, ranging from 17 to 82 %,
which may further explain the gap in the awareness of fatigue
between HCPs and patients [1–3]. While we did not examine
whether patients were participating in an exercise or rehabili-
tation program, exercise has emerged as an effective treatment
for fatigue in patients with cancer [18].
Patient-reported and HCP perceptions of the impact of pain
on daily life also showed differences between patients and
HCPs. Thirty percent of oncologists and 29 % of oncology
nurses believed that pain had a greater impact than fatigue on
daily life while undergoing treatment with chemotherapy,
compared with only 18 % of patients that reported this per-
ception. Compared with fatigue, pain may be better controlled
among chemotherapy patients due to the effectiveness of pain
management plans in patients with cancer. Furthermore, the
differential between HCP and patient perceptions of the
impact of pain on daily life may lead HCPs to treat pain more
aggressively, leading to the decreased impact of pain relative
to fatigue reported by patients.
Studies such as ours may lead to increased awareness of the
need for the assessment of fatigue symptoms on an ongoing
basis in patients with cancer in the clinic. In our study, 29% of
oncologists and 25 % of oncology nurses perceive that fatigue
impacts daily life more than pain, whereas 58 % of patients
have this perception. The capture of PROs through electronic
medical records may facilitate discussions between patients
and the multidisciplinary clinical management team, which
may lead to increased recognition of and targeted treatment
for subjective symptoms such as fatigue and pain.
Management plans to increase HCP awareness of fatigue
symptoms for patients at-risk of or experiencing fatigue, as
well as educational programs to help patients and primary
caregivers recognize fatigue symptoms, may be helpful in
controlling symptoms of fatigue, thereby increasing quality
of life in patients with cancer.
Potential biases and limitations
Given this study’s nonrandom sampling from an internet
survey panel, selection bias may be a limitation since the
respondent was on an email list and then self-selected to
participate in the study. Selection bias may have also
prevented patients from participating, particularly for less
internet-literate patients. In addition, patients with lower
income may have less access to internet services and may
not have participated as frequently as patients with higher
income [19].
Patients were asked in the survey (Appendix) to answer
questions about “fatigue during your treatment with chemo-
therapy”; therefore, it is possible that the fatigue patients re-

























Paents (N = 550) Oncologists (N = 400) Nurses (N = 400)
Fig. 1 Perception of the impact
of fatigue and pain on daily life
during chemotherapy
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chemotherapy. Measurement errors from patients can occur
from the questions being misunderstood or from recall bias
to the experiences during chemotherapy, potentially resulting
in information bias. Historical publications mention that cancer
patient survey responses could be affected by recall bias due to
potential cognitive impairment related to chemotherapy.
Measures taken to minimize bias at the study design
or analysis stage
At the study design level, a multiphase approach was im-
plemented to minimize subject selection bias. One method
to minimize bias was through a pretest feedback survey
conducted with five each of patients, nurses, and physi-
cians that were not enrolled onto the study. To minimize
recall bias, eligibility criteria were set such that patients
were excluded from the survey if they had been off che-
motherapy >1 year, ensuring that the study sampled a pop-
ulation on or recently off chemotherapy, essentially limit-
ing potential recall bias.
Generalizability of findings
The study findings may not be generalizable to the US
population. Most patients reported that they were non-
Hispanic and women (95.5 and 73.8 % respectively),
whereas the US census bureau reports that Hispanics con-
stituted 16.7 % of the nation’s total population, and as of
2011 , 50 .8 % were fema le (www.census .gov ) .
Furthermore, the study findings may not be generalizable
to the cancer population. For example, comparing patients
in the current study to those included in the Oncology
Services Comprehensive Electronic Records (OSCER) da-
tabase, a larger proportion of study patients fall into the 45-
to 55-year-old category (24 vs 17.6 %) and fewer fall into
the >75-year range (7.3 vs 17.6 %). In this study, 38.5 % of
patients had breast cancer, whereas 28.7 % of the OSCER
database are women with breast cancer. Perhaps most im-
portantly, the sample may be overrepresented by symptom-
atic patients, given the high proportion of people with
ECOG performance status ≥2 [20]. Patients with decreased
performance status were possibly experiencing more
Table 3 Patient-reported fatigue and pain severity scores
Experiencing fatigue
(score > 0)—n (%)
Not experiencing fatigue
(score = 0)—n (%)
Experiencing pain
(score > 0)—n (%)
Not experiencing pain
(score = 0)—n (%)
Overall (N = 550) 536 (97.5) 14 (2.5) 474 (86.2) 76 (13.8)
By tumor type
Breast (n = 212) 207 (97.6) 5 (2.4) 182 (85.8) 30 (14.2)
Genitourinary (n= 51) 48 (94.1) 3 (5.9) 47 (92.2) 4 (7.8)
Lung (n= 74) 74 (100.0) 0 (0) 64 (86.5) 10 (13.5)
Gastrointestinal (n= 98) 96 (98.0) 2 (2.0) 73 (74.5) 25 (25.5)
Gynecologic (n= 69) 69 (100.0) 0 (0) 67 (97.1) 2 (2.9)
Other (n= 46) 42 (91.3) 4 (8.7) 41 (89.1) 5 (10.9)
By ECOG performance status
0 (n= 30) 21 (70.0) 9 (30.0) 15 (50) 15 (50)
1 (n= 198) 194 (98.0) 4 (2.0) 161 (81.3) 37 (18.7)
2 (n= 173) 172 (99.4) 1 (0.6) 159 (91.9) 14 (8.1)
3 (n= 135) 135 (100.0) 0 (0) 126 (93.3) 9 (6.7)
4 (n= 14) 14 (100.0) 0 (0) 13 (92.9) 1 (7.1)
By gender
Male (n= 144) 139 (96.5) 5 (3.5) 123 (85.4) 21 (14.6)
Female (n= 406) 397 (97.8) 9 (2.2) 351 (86.5) 55 (13.5)
By metastatic disease status
Yes (n = 235) 234 (99.6) 1 (0.4) 207 (88.1) 28 (11.9)
No (n= 315) 302 (95.9) 13 (4.1) 267 (84.8) 48 (15.2)
By time since diagnosis
≤1 year (n= 184) 182 (98.9) 2 (1.1) 157 (85.3) 27 (14.7)
>1 and ≤3 years (n= 170) 164 (96.5) 6 (3.5) 149 (87.6) 21 (12.4)
>3 and ≤5 years (n= 66) 65 (98.5) 1 (1.5) 51 (77.3) 15 (22.7)
>5 years (n= 130) 125 (96.2) 5 (3.8) 117 (90.0) 13 (10.0)
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problems with pain and fatigue and may have been more
likely to respond to the survey.
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